STOCK TITAN

Spyre Therapeutics, Inc. reported $0 in revenue and a $155.2M net loss for fiscal 2025. See the full SYRE financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

[SCHEDULE 13G] Spyre Therapeutics, Inc. SEC Filing

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The holdings reported herein include securities in the form of rights.The CUSIP Number listed throughout this filing is the CUSIP assigned to the Ordinary Shares of the Issuer.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:07/29/2025